PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-3.83%
Negative ROE while Drug Manufacturers - Specialty & Generic median is 1.19%. Seth Klarman would investigate if capital structure or industry issues are at play.
-3.71%
Negative ROA while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-4.10%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate whether a turnaround is viable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.